Probiome Therapeutics Inc is a newly formed Iowa-based company in Ames, dedicated to collaborative translational research and technology transfer in the field of gut microbial genetic engineering and pharmacogenomics. Their focus lies in developing innovative oral probiotic-based therapies to address incurable chronic conditions, including neurodegenerative diseases and COVID-19.
With a team of talented scientists, Probiome Therapeutics aims to reengineer probiotic EcN drug delivery through the gut-CNS axis, offering potential solutions for major diseases. As a development-stage company, they value partnerships, collaborations, and equity investments from pharmaceutical industries and venture capital investors who recognize the long-term value of investing in their groundbreaking work.
Generated from the website